#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Chris Kirton Email
CEO . DefiniGEN
Cambridge,
LocationPrimary Email
How to contact Chris Kirton
Join and see Chris's contact info for free!Current Roles
Employees:
37Revenue:
$5.7MAbout
DefiniGEN was founded in 2012 to industrialise the OptiDIFF stem cell production platform developed at the University of Cambridge, UK. DefiniGEN has world-leading expertise in the area of human induced pluripotent stem cell (iPSC) derived cell production and metabolic disease modelling. The company's key scientific founder Prof. Ludovic Vallier from the University of Cambridge and Dr. Tamir Rashid from Kings College London. The company has built on the intellectual property and knowledge resident at the University of Cambridge - Laboratory for Regenerative Medicine at Addenbrooke's Hospital and has in-licensed the Nobel Prize winning Yamanka iPSC intellectual property portfolio from iPS Academia Japan Inc. DefiniGEN offers human iPSC derived disease modelled hepatocytes (Def-HEP) and pancreatic cell (Def-PANC) range of products to the pharmaceutical and life science sectors for drug discovery and disease modelling research. In addition DefiniGEN also provides contract research services and has tremendous expertise in the areas of cell model development, assay development, drug safety and efficacy screening. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products in essentially unlimited quantities and on a predictable timetable enabling the development of safer and more effective treatments.DefiniGEN Address
Babraham Research CampusCambridge, null